Skip to content

Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease

Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00609752
Enrollment
80
Registered
2008-02-07
Start date
2008-02-29
Completion date
2010-01-31
Last updated
2008-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn Disease

Keywords

Crohn Disease, Children, Bone Density, Prednisolone, Liquid Diet Therapy, Quality of Life, Metabolic Bone Disease

Brief summary

This study will compare two current first-line treatments for childhood Crohn's Disease, steroids versus a liquid diet, and determine the effects of these treatments on bone health, quality of life and treatment efficacy.

Detailed description

Crohn's Disease is a very serious inflammatory gut disorder that often first presents in childhood. Once present, the underlying condition remains for life. It usually responds well to medical treatment which brings about a disease 'remission' but is inclined to become active again at intervals (relapses). When it is active, children are very unwell with reduced energy, loss of appetite and distressing abdominal symptoms (pain, diarrhea, etc.). Active disease can be treated in two very different ways - either with a 3-month course of steroids (tablets), or with a 6-week course of so called liquid diet therapy (LDT). With LDT, children receive all of their nutrition in liquid form. Both treatments have advantages and disadvantages. Both are quite effective, often controlling symptoms within days. Steroids may cause various side effects including thinning of bones (osteoporosis) with increased risk of fractures. LDT is somewhat challenging because normal (solid) foods are not allowed during the period of treatment. Both steroids and LDT are widely used - steroids predominately in the USA and LDT elsewhere. There is controversy as to which is best. This study aims to determine which should be preferred. In this clinical study, children presenting with Crohn's disease will be randomly assigned to either steroid treatment or LDT and followed up for a period of one year. During that time the assigned treatment will be used for any episodes of active disease. We will study a total of 80 children attending the Paediatric Gastroenterology Units in Birmingham, Bristol, Liverpool, Oxford, Sheffield and St. George's Hospital in London. Various outcomes will be compared in the two groups. We will examine the recovery rates (success in bringing about remission) and the frequency of subsequent relapses. We will compare growth and physical development, because active Crohn's disease and possibly steroids may have adverse effects on these processes. A special focus of the study will be on the effect of the disease and its treatment on bone health. Using special blood and urine tests and bone scans we will compare bone growth and density in the two groups. Finally, it is crucially important that we consider the impact of the disease and its treatment on the young person on the basis of their own individual perspective. To do this we will compare the 'quality of life' of children in the two treatment groups, using a questionnaire specially designed to measure this aspect in young people with Crohn's disease. This study will thus enable us to undertake a comprehensive comparison of the two major first-line treatments used in childhood Crohn's Disease. This is crucially important, and no such study has previously been undertaken

Interventions

DRUGprednisolone

Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.

DIETARY_SUPPLEMENTAlicalm (polymeric liquid formula)

Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a normal unrestricted diet by 10 weeks.

Sponsors

SHS International
CollaboratorUNKNOWN
Children's Memorial Research Foundation
CollaboratorUNKNOWN
St George's University Hospital Research Foundation
CollaboratorUNKNOWN
University Hospital Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
7 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Active Crohn's Disease with PCDAI \> 20 * Aged 7 - 17 with possibility of 1 year follow-up

Exclusion criteria

* Previous treatment for Crohn's Disease with liquid diet or glucocorticoid therapy * Isolated orofacial granulomatosis * Intravenous glucocorticoid therapy immediately indicated * Planned surgical intervention for CD

Design outcomes

Primary

MeasureTime frame
Bone mineral density change based on DXA measurement at 1 year12 months post-recruitment

Secondary

MeasureTime frame
Change in PCDAI, HAB and pHBS6 weeks
Quality of life throughout treatment period, using IMPACT III measurements12 months
Baseline urine 11B-HSD1 and bone formation6 weeks
Baseline urine 11B-HSD1 activity and change in bone mineral density12 months
Proportion in remission6 weeks
Growth impairment12 months
Adherence to randomised therapy for relapses12 months
Adverse effects12 months
Change in urine 11B-HSD1 activity and PCDAI in patients before and after treatment with LDT and CST12 months

Countries

United Kingdom

Contacts

Primary ContactM. Stephen Murphy
m.s.murphy@bham.ac.uk+44 (0)121 333 8705
Backup ContactKelly Spencer
k.spencer@bham.ac.uk+44 (0)121 333 9542

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026